Search Results - "Chambers, Mara"

Iron deficiency anemia by Killip, Shersten, Bennett, John M, Chambers, Mara D

“…The prevalence of iron deficiency anemia is 2 percent in adult men, 9 to 12 percent in non-Hispanic white women, and nearly 20 percent in black and…”
Get full text

Plasma TNF-α and Soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna-A Randomized, Cross-Over Clinical Study by Hayslip, John, Dressler, Emily V, Weiss, Heidi, Taylor, Tammy J, Chambers, Mara, Noel, Teresa, Miriyala, Sumitra, Keeney, Jeriel T R, Ren, Xiaojia, Sultana, Rukhsana, Vore, Mary, Butterfield, D Allan, St Clair, Daret, Moscow, Jeffrey A

“…Chemotherapy-induced cognitive impairment (CICI) is a common sequelae of cancer therapy. Recent preclinical observations have suggested that CICI can be…”
Get full text

Communication with physicians and family about breast Cancer recurrence by Kelly, Kimberly M., Rai, Pragya, Studts, Jamie L., Dickinson, Stephanie, Henschel, Beate, Dignan, Mark, Chambers, Mara, Hazard-Jenkins, Hannah

“…Adequate physician-patient communication about cancer recurrence is vital to quality of life and to informed decision-making related to survivorship care. The…”
Get full text

Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer by Williams, Nicole O., Quiroga, Dionisia, Johnson, Courtney, Brufsky, Adam, Chambers, Mara, Bhattacharya, Saveri, Patterson, Maria, Sardesai, Sagar D., Stover, Daniel, Lustberg, Maryam, Noonan, Anne M., Cherian, Mathew, Bystry, Darlene M., Hill, Kasey L., Chen, Min, Phelps, Mitch A., Grever, Michael, Stephens, Julie A., Ramaswamy, Bhuvaneswari, Carson, William E., Wesolowski, Robert

“…Background: Heat shock protein 90 (HSP90) is a molecular chaperone required for stabilization of client proteins over-activated in triple-negative breast…”
Get full text

Ki-67 Testing in Breast Cancer: Assessing Variability With Scoring Methods and Specimen Types and the Potential Subsequent Impact on Therapy Eligibility by Bocklage, Therese, Cornea, Virgilius, Hickey, Caylin, Miller, Justin, Moss, Jessica, Chambers, Mara, Bachert, S Emily

“…Abemaciclib was originally FDA approved for patients with ER-positive/HER2-negative breast cancer with Ki-67 expression ≥20%. However, there were no guidelines…”
Get full text

Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research by Alqaisi, Abeer, Chen, Li, Romond, Edward, Chambers, Mara, Stevens, Mark, Pasley, Grace, Awasthi, Mukta, Massarweh, Suleiman

“…ER and HER2 are critical drivers of breast cancer biology and can interact when co-expressed, but less data describe the impact of ER/HER2 co-expression on…”
Get full text

Neglected breast cancer in the Appalachians by Arays, Ruta, Tran-Harding, Karen, Wu, Jianrong, Yan, Donglin, Durbin, Eric B., Marcinkowski, Emily Fontenot, McGrath, Patrick, Hawthorne, Kelly, Romond, Edward H., Chambers, Mara D., Gibbs, Richard, Mathew, Aju

“…Abstract only…”
Get full text

A Narrative Review of the Confluence of Breast Cancer and Low-wage Employment and Its Impact on Receipt of Guideline-recommended Treatment by Vanderpool, Robin C., Swanberg, Jennifer E., Chambers, Mara D.

“…Breast cancer is the leading cause of cancer among women in the United States, costing the healthcare system, employers, and society billions of dollars each…”
Get full text

Impact of estrogen receptor co-expression on breast cancer disease characteristics: implications for tumor biology and research by Alqaisi, Abeer, Chen, Li, Romond, Edward, Chambers, Mara, Stevens, Mark, Pasley, Grace, Awasthi, Mukta, Massarweh, Suleiman

“…ER and HER2 are critical drivers of breast cancer biology and can interact when co-expressed, but less data describe the impact of ER/HER2 co-expression on…”
Get full text

Abstract 7632: Final survival outcomes and post-hoc tumor gene expression pathway analyses of complete responders from a phase Ib clinical trial of HSP90 inhibitor onalespib and paclitaxel in patients with advanced triple-negative breast cancer by Quiroga, Dionisia Marie, Savardekar, Himanshu, Schwarz, Emily, Williams, Nicole O., Johnson, Courtney, Brufsky, Adam, Chambers, Mara, Bhattacharya, Saveri, Patterson, Maria, Sardesai, Sagar D., Stover, Daniel, Lustberg, Maryam, Noonan, Anne, Cherian, Mathew, Bystry, Darlene M., Hill, Kasey, Chen, Min, Phelps, Mitch A., Stephens, Julie, Yu, Lianbo, Ramaswamy, Bhuvaneswari, Wesolowski, Robert, Carson, William E.

“…Abstract Background: Heat shock protein 90 (HSP90) is a molecular chaperone required for stabilization of client proteins over-activated in triple-negative…”
Get full text

Evaluation of possible linkage between everolimus benefit in estrogen receptor (ER)-positive breast cancer and genomic alterations of the PI3K/AKT/mTOR pathway by Black, Esther P., Romond, Edward H., Chmielecki, Juliann, Sun, James, Kadamyan, Vera, Chambers, Mara D., Stewart, Rachel Lauren, Dressler, Emily Van Meter, Mehdi, Murtaza, Horbinski, Craig, Massarweh, Suleiman Alfred

“…Abstract only…”
Get full text

Effect of mutations in distinct components of the PI3K/AKT/mTOR pathway on sensitivity to endocrine therapy in estrogen receptor (ER)-positive breast cancer by Massarweh, Suleiman Alfred, Chmielecki, Juliann, Sun, James, Stewart, Rachel Lauren, Dressler, Emily Van Meter, Kadamyan, Vera, Chambers, Mara D., Horbinski, Craig, Mehdi, Murtaza, Black, Esther P., Romond, Edward H.

“…Abstract only…”
Get full text

Utility of comprehensive genomic profiling (CGP) at an NCI-designated cancer center for identifying clinically relevant genomic alterations (CRGA) and implementing genomically directed therapy (GDT) by Hilal, Talal, Nakazawa, Mary, Hodskins, Jacob, Arnold, Susanne M., DeSimone, Philip A., Wagner, Lars M., Anthony, Lowell Brian, Chambers, Mara D., Villano, John L., Mathew, Aju, Bayliff, Sherry L., Goel, Gaurav, Romond, Edward H., Thind, Ravneet, Wang, Peng, Badgett, Tom C., D'Orazio, John A., Ueland, Fredrick R., VanNagell, John, Hosein, Peter Joel

“…Abstract only…”
Get full text

Plasma TNF-[alpha] and Soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna-A Randomized, Cross-Over Clinical Study by Hayslip, John, Dressler, Emily V, Weiss, Heidi, Taylor, Tammy J, Chambers, Mara, Noel, Teresa, Miriyala, Sumitra, Keeney, Jeriel T. R, Ren, Xiaojia, Sultana, Rukhsana, Vore, Mary, Butterfield, D. Allan, St Clair, Daret, Moscow, Jeffrey A

“…Purpose Chemotherapy-induced cognitive impairment (CICI) is a common sequelae of cancer therapy. Recent preclinical observations have suggested that CICI can…”
Get full text

A phase II study of combined fulvestrant and everolimus in metastatic estrogen receptor (ER)+ breast cancer after aromatase inhibitor (AI) failure by Massarweh, Suleiman Alfred, Romond, Edward H., Croley, Jessica Jones, Black, Esther P., Chambers, Mara D., Stevens, Mark, Shelton, Brent, Kadamyan, Vera, Elledge, Richard M.

“…Abstract only 541 Background: Fulvestrant, an ER downregulator, can be effective in metastatic ER+ breast cancer but resistance is a problem. Everolimus…”
Get full text

Iron Deficiency Anemia by Killip, Shersten, Bennett, John M, Chambers, Mara D

“…The prevalence of iron deficiency anemia is 2 percent in adult men, 9 to 12 percent in non-Hispanic white women, and nearly 20 percent in black and…”
Get full text

Plasma TNF- alpha and Soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna-A Randomized, Cross-Over Clinical Study: e0124988 by Hayslip, John, Dressler, Emily V, Weiss, Heidi, Taylor, Tammy J, Chambers, Mara, Noel, Teresa, Miriyala, Sumitra, Keeney, Jeriel TR, Ren, Xiaojia, Sultana, Rukhsana

“…Purpose Chemotherapy-induced cognitive impairment (CICI) is a common sequelae of cancer therapy. Recent preclinical observations have suggested that CICI can…”
Get full text